• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在美国,母体血浆DNA检测是否正在影响基于血清的非整倍体筛查?

Is maternal plasma DNA testing impacting serum-based screening for aneuploidy in the United States?

作者信息

Palomaki Glenn E, Ashwood Edward R, Best Robert G, Lambert-Messerlian Geralyn, Knight George J

机构信息

Division of Medical Screening and Special Testing, Department of Pathology and Laboratory Medicine, Women & Infants Hospital, Alpert Medical School of Brown University, Providence, Rhode Island, USA.

ARUP Laboratories, Department of Pathology, University of Utah School of Medicine, Salt Lake City, Utah, USA.

出版信息

Genet Med. 2015 Nov;17(11):897-900. doi: 10.1038/gim.2015.39. Epub 2015 Apr 2.

DOI:10.1038/gim.2015.39
PMID:25834952
Abstract

PURPOSE

We sought to determine whether tests for fetal aneuploidy based on next-generation sequencing of cell-free DNA in maternal circulation have had an impact on routine serum-based screening in the general pregnant population.

METHODS

We compared results from laboratory surveys in 2011 and 2014 that reported types of prenatal serum screening tests and numbers of tests performed. Testing records from two prenatal serum screening laboratories examined temporal trends in the proportion of screened women 35 years of age and older from 2008 (or 2009) to 2014.

RESULTS

The 82 laboratory survey results available for comparison showed that 1.7 million women were screened in 2014, a 5% increase over 2011. In the two screening laboratories, the proportion of screened women age 35 and older increased for several years but then experienced reductions of 8 and 18% by mid-2014 when compared with the highest rates observed.

CONCLUSION

As of 2014, maternal plasma DNA testing appears to have had only a minor impact on serum screening rates in the United States. Ongoing surveillance has the potential to determine if, and when, DNA testing begins to replace serum testing as a primary screen for Down syndrome in the United States.

摘要

目的

我们试图确定基于孕妇循环中游离DNA的下一代测序进行的胎儿非整倍体检测是否对普通孕妇群体的常规血清学筛查产生了影响。

方法

我们比较了2011年和2014年实验室调查的结果,这些结果报告了产前血清学筛查检测的类型和检测数量。来自两个产前血清学筛查实验室的检测记录研究了2008年(或2009年)至2014年35岁及以上受筛查女性比例的时间趋势。

结果

可用于比较的82份实验室调查结果显示,2014年有170万女性接受了筛查,比2011年增加了5%。在这两个筛查实验室中,35岁及以上受筛查女性的比例连续数年上升,但到2014年年中,与观察到的最高比例相比,分别下降了8%和18%。

结论

截至2014年,孕妇血浆DNA检测似乎对美国的血清学筛查率影响较小。持续监测有可能确定在美国DNA检测是否以及何时开始取代血清学检测作为唐氏综合征的主要筛查方法。

相似文献

1
Is maternal plasma DNA testing impacting serum-based screening for aneuploidy in the United States?在美国,母体血浆DNA检测是否正在影响基于血清的非整倍体筛查?
Genet Med. 2015 Nov;17(11):897-900. doi: 10.1038/gim.2015.39. Epub 2015 Apr 2.
2
Prenatal screening for fetal aneuploidy in singleton pregnancies.单胎妊娠胎儿非整倍体的产前筛查。
J Obstet Gynaecol Can. 2011 Jul;33(7):736-750. doi: 10.1016/S1701-2163(16)34961-1.
3
DNA sequencing versus standard prenatal aneuploidy screening.DNA 测序与标准产前非整倍体筛查。
N Engl J Med. 2014 Feb 27;370(9):799-808. doi: 10.1056/NEJMoa1311037.
4
Committee Opinion Summary No. 640: Cell-Free DNA Screening For Fetal Aneuploidy.委员会意见摘要第640号:游离DNA筛查胎儿非整倍体
Obstet Gynecol. 2015 Sep;126(3):691-692. doi: 10.1097/01.AOG.0000471171.86798.ac.
5
Committee Opinion No. 640: Cell-Free DNA Screening For Fetal Aneuploidy.第640号委员会意见:游离DNA筛查胎儿非整倍体。
Obstet Gynecol. 2015 Sep;126(3):e31-e37. doi: 10.1097/AOG.0000000000001051.
6
The clinical utility of DNA-based screening for fetal aneuploidy by primary obstetrical care providers in the general pregnancy population.在一般妊娠人群中,初级产科保健提供者进行基于 DNA 的胎儿非整倍体筛查的临床实用性。
Genet Med. 2017 Jul;19(7):778-786. doi: 10.1038/gim.2016.194. Epub 2017 Jan 12.
7
Have we done our last amniocentesis? Updates on cell-free DNA for Down syndrome screening.我们是否已进行了最后一次羊膜穿刺术?唐氏综合征筛查中游离DNA检测的最新进展。
Pediatr Radiol. 2018 Apr;48(4):461-470. doi: 10.1007/s00247-017-3958-y. Epub 2018 Mar 17.
8
No. 261-Prenatal Screening for Fetal Aneuploidy in Singleton Pregnancies.第261号——单胎妊娠胎儿非整倍体的产前筛查
J Obstet Gynaecol Can. 2017 Sep;39(9):e380-e394. doi: 10.1016/j.jogc.2017.06.013.
9
Noninvasive prenatal testing of fetal aneuploidies by massively parallel sequencing in a prospective Chinese population.大规模平行测序在中国人前瞻性人群中进行的胎儿非整倍体无创性产前检测。
Prenat Diagn. 2013 Jul;33(7):700-6. doi: 10.1002/pd.4160. Epub 2013 Jun 17.
10
Noninvasive Prenatal Testing and Incidental Detection of Occult Maternal Malignancies.非侵入性产前检测与隐匿性母体恶性肿瘤的意外发现。
JAMA. 2015 Jul 14;314(2):162-9. doi: 10.1001/jama.2015.7120.

引用本文的文献

1
The clinical utility of DNA-based screening for fetal aneuploidy by primary obstetrical care providers in the general pregnancy population.在一般妊娠人群中,初级产科保健提供者进行基于 DNA 的胎儿非整倍体筛查的临床实用性。
Genet Med. 2017 Jul;19(7):778-786. doi: 10.1038/gim.2016.194. Epub 2017 Jan 12.